- Home
- FATE vs BMN Comparison
FATE vs BMN Comparison
Compare FATE & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- BMN
- Stock Information
- Founded
- FATE 2007
- BMN 2020
- Country
- FATE United States
- BMN United States
- Employees
- FATE N/A
- BMN 19800
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- BMN Trusts Except Educational Religious and Charitable
- Sector
- FATE Health Care
- BMN Finance
- Exchange
- FATE Nasdaq
- BMN Nasdaq
- Market Cap
- FATE 177.7M
- BMN 146.9M
- IPO Year
- FATE 2013
- BMN N/A
- Fundamental
- Price
- FATE $1.18
- BMN $25.03
- Analyst Decision
- FATE Hold
- BMN
- Analyst Count
- FATE 7
- BMN 0
- Target Price
- FATE $3.83
- BMN N/A
- AVG Volume (30 Days)
- FATE 2.0M
- BMN 29.9K
- Earning Date
- FATE 08-12-2025
- BMN 01-01-0001
- Dividend Yield
- FATE N/A
- BMN 4.66%
- EPS Growth
- FATE N/A
- BMN N/A
- EPS
- FATE N/A
- BMN N/A
- Revenue
- FATE $13,335,000.00
- BMN N/A
- Revenue This Year
- FATE N/A
- BMN N/A
- Revenue Next Year
- FATE N/A
- BMN N/A
- P/E Ratio
- FATE N/A
- BMN N/A
- Revenue Growth
- FATE 105.85
- BMN N/A
- 52 Week Low
- FATE $0.66
- BMN $21.51
- 52 Week High
- FATE $5.92
- BMN $25.59
- Technical
- Relative Strength Index (RSI)
- FATE 46.59
- BMN 64.48
- Support Level
- FATE $1.16
- BMN $24.51
- Resistance Level
- FATE $1.32
- BMN $25.05
- Average True Range (ATR)
- FATE 0.16
- BMN 0.37
- MACD
- FATE -0.04
- BMN 0.05
- Stochastic Oscillator
- FATE 8.33
- BMN 69.44
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest
BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.